Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.


Pieber T., Bode B., Mertens A., Cho Y., Christiansen E., Hertz C., ...Daha Fazla

The lancet. Diabetes & endocrinology, cilt.7, ss.528-539, 2019 (SCI-Expanded) identifier identifier identifier